title: Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia.
abstract: BACKGROUND
  Colestimide has been reported to lower blood glucose levels in patients with type 2 diabetes complicated by hypercholesterolemia.
  
  
  OBJECTIVE
  To examine the mechanism by which colestimide decreases plasma glucose levels in the above patients.
  
  
  METHODS
  A total of 16 inpatients with type 2 diabetes complicated by hypercholesterolemia received colestimide for 1 week after their plasma glucose levels stabilized. We measured plasma glucose, serum immunoreactive insulin (IRI), serum lipid, plasma glucagon, and plasma glucagon-like peptide-1 (GLP-1) levels. These variables at baseline and 1 week of colestimide administration were compared.
  
  
  RESULTS
  Preprandial plasma glucose levels (baseline: 132 +/- 33 mg/dL vs. completion: 118 +/- 43 mg/dL, P=0.073) tended to decrease after colestimide administration, while 1-hr postprandial plasma glucose levels (baseline: 208 +/- 49 mg/dL vs. completion: 166 +/- 30 mg/dL, P<0.001) and 2-hr postprandial plasma glucose levels (baseline: 209 +/- 56 mg/dL vs. completion: 178 +/- 39 mg/dL, P=0.015) decreased significantly at 1 week of colestimide administration. The 2-hr postprandial plasma GLP-1 level was significantly (P=0.015) higher at 1 week of colestimide administration as compared with the baseline level, while there were no significant changes in preprandial and 1-hr postprandial plasma GLP-1 levels.
  
  
  CONCLUSIONS
  The GLP-1-increasing activity of colestimide may explain, at least in part, the mechanism of its blood glucose-lowering activity in patients with type 2 diabetes complicated by hypercholesterolemia.
authors.affiliation: Department of Functional Pathophysiology for Human Organs, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan. t.suzuki@nms.ac.jp
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Suzuki
authors.forename: Kenzo
authors.initials: K
authors.lastname: Oba
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Igari
authors.forename: Noriaki
authors.initials: N
authors.lastname: Matsumura
authors.forename: Kentaro
authors.initials: K
authors.lastname: Watanabe
authors.forename: Shoko
authors.initials: S
authors.lastname: Futami-Suda
authors.forename: Hiroko
authors.initials: H
authors.lastname: Yasuoka
authors.forename: Motoshi
authors.initials: M
authors.lastname: Ouchi
authors.forename: Kazunari
authors.initials: K
authors.lastname: Suzuki
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Kigawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nakano
mesh_terms: D000837:Anion Exchange Resins; D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D004811:Epichlorohydrin / Q000008:administration & dosage*; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000097:blood; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000150:complications* / Q000188:drug therapy*; D007093:Imidazoles / Q000008:administration & dosage*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D012117:Resins, Synthetic / Q000008:administration & dosage*
chemical_list: D000837:Anion Exchange Resins; D001786:Blood Glucose; D007093:Imidazoles; D008055:Lipids; D012117:Resins, Synthetic; C417427:colestimide; D004811:Epichlorohydrin; D052216:Glucagon-Like Peptide 1